We strongly believe that early phase clinical trials can be designed to provide critical proof-of-concept data faster and more cost-efficient. Without compromising on quality, the INFECTA team takes pride in designing fit-for-purpose early phase clinical trials which aim to maximally de-risk your clinical development path.
We provide a wide range of services for the development of vaccines, therapeutics, antivirals and biologics. We use and develop various clinical research methodologies and hold the largest global portfolio of controlled human infection models (CHIMs).
Emerging from the longstanding collaboration between Dutch University Medical Centers and as a spinout of the Centre for Human Drug Research (CHDR), we have a strong legacy in early phase clinical research programs and a solid scientific foundation, including decades of experience with CHIMs.
We can become your trusted partner during the clinical development of your infectious diseases’ compounds and provide support with the following activities:
We are a full-service CRO with over thirty years of experience in healthy volunteer studies. We design your trial, draft the protocol and submission package, and guide it through the regulatory process according to the agreed timelines and standards.
We are internationally recognized for CHIM expertise. When appropriate and ethically approved, CHIMs can substantially accelerate infectious-disease product development by enabling early, decision-quality read-outs.
INFECTA operates a fully equipped laboratory up to BSL-3 for sample processing. Safety, virology and bacteriology endpoint assays are performed in-house or via accredited partner labs.
Building on decades of experience in early-phase development, we help map the path from candidate to first-in-human and beyond.
Controlled human infection models (CHIMs) are powerful tools that can be used to study host-pathogen interaction in specific infections, as well as test efficacy of novel therapeutics and vaccines. CHIMs enable a swift and cost-efficient assessment of drug safety and efficacy early in clinical development, de-risking your future clinical development path.
With 10+ years of experience in performing CHIMs, the INFECTA team will carefully balance risks and benefits of these models for your product and give you insights into what you can or cannot learn from them. The INFECTA team manages the regulatory and operational complexities of these studies, selects the pathogen and has protocols available for the exposure and clinical follow up of the volunteers. Endpoints can be clinical, microbiological and immunological. We can ensure the consistence and robustness of the trials.
We already have an extensive portfolio of CHIMs, and are continuing to develop more. All CHIMs are developed in collaboration with our academic partners.
Our CHIMs support research across a range of respiratory and vector-borne viruses, such as Dengue & Influenza.
Our repository of CHIMs including Bordetella Pertussis and Pneumococcus provides a valuable platform.
With our CHIMs for parasites like Malaria & Hookworm, you can ensure that your process is sped-up.
December 2, 2025
November 26, 2025
Today our COO Ingrid de Visser-Kamerling was live on the BNR Nieuwsradio with Koenraad Wiedhaup to talk about the recent developments in infectious disease…
November 25, 2025
Leiden, 26 November 2025 – INFECTA, a Dutch clinical research organization specializing in infectious diseases, has signed a collaboration agreement with AHAM Vastgoed for…
November 4, 2025
Celebrating our 1 year anniversary at the first FAST – Centre for Future Affordable Sustainable Therapy Development event today with cake!
…If you would like to explore how INFECTA can help you bring your pharmaceutical product to the next level, contact us with the form, or reach out to info@infecta.org
